New, Old, and Shared Antibody Specificities in Autoimmune Diseases
1. Introduction
2. Overview of the Published Articles in the Special Issue “New, Old, and Shared Antibody Specificities in Autoimmune Diseases”
2.1. Contribution 1
2.2. Contribution 2
2.3. Contribution 3
2.4. Contribution 4
2.5. Contribution 5
3. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
List of Contributions
- Palazzo, R; Stefanantoni, K; Cadar, M; Butera, A; Riccieri, V; Lande, R; Frasca, L. Heparin-Independent and Heparin-Dependent Anti-CXCL4 Antibodies Have a Reciprocal Expression in a Systemic Sclerosis Patients’ Cohort. Antibodies 2022, 11, 77. https://doi.org/10.3390/antib11040077.
- Lande, R; Palazzo, R; Mennella, A; Pietraforte, I; Cadar, M; Stefanantoni, K; Conrad, C; Riccieri, V; Frasca, L. New Autoantibody Specificities in Systemic Sclerosis and Very Early Systemic Sclerosis. Antibodies 2021, 10, 12. https://doi.org/10.3390/antib10020012.
- Valeich, J; Boyd, D; Kanwar, M; Stenzel, D; De Ghosh, D; Ebrahimi, A; Woo, J; Wang, J; Ambrogelly, A. Taking the Hinge off: An Approach to Effector-Less Monoclonal Antibodies. Antibodies 2020, 9, 50. https://doi.org/10.3390/antib9040050.
- Biswas, T.K.; VanderLaan, P.A.; Que, X; Gonen, A.; Krishack, P.; Binder, C.J.; Witztum, J.L.; Getz, G.S.; Reardon, C.A. CD1d Selectively Down Regulates the Expression of the Oxidized Phospholipid-Specific E06 IgM Natural Antibody in Ldlr−/− Mice. Antibodies 2020, 9, 30. https://doi.org/10.3390/antib9030030.
- Hysa, E.; Campitiello, R.; Sammorì, S.; Gotelli, E.; Cere, A.; Pesce, G.; Pizzorni, C.; Paolino, S.; Sulli, A.; Smith, V.; Cutolo, M. Specific Autoantibodies and Microvascular Damage Progression Assessed by Nailfold Videocapillaroscopy in Systemic Sclerosis: Are There Peculiar Associations? An Update. Antibodies 2023, 12, 3. https://doi.org/10.3390/antib12010003.
References
- Ho, Y.Y.; Lagares, D.; Tager, A.M.; Kapoor, M. Fibrosis—A Lethal Component of Systemic Sclerosis. Nat. Rev. Rheumatol. 2014, 10, 390–402. [Google Scholar] [CrossRef]
- Denton, C.P.; Khanna, D. Systemic Sclerosis. Lancet 2017, 390, 1685–1699. [Google Scholar] [CrossRef]
- Frasca, L.; Palazzo, R.; Chimenti, M.S.; Alivernini, S.; Tolusso, B.; Bui, L.; Botti, E.; Giunta, A.; Bianchi, L.; Petricca, L.; et al. Anti-LL37 Antibodies Are Present in Psoriatic Arthritis (PsA) Patients: New Biomarkers in PsA. Front. Immunol. 2018, 9, 1936. [Google Scholar] [CrossRef] [PubMed]
- Sitko, K.; Bednarek, M.; Mantej, J.; Trzeciak, M.; Tukaj, S. Circulating Heat Shock Protein 90 (Hsp90) and Autoantibodies to Hsp90 Are Increased in Patients with Atopic Dermatitis. Cell Stress Chaperones 2021, 26, 1001–1007. [Google Scholar] [CrossRef] [PubMed]
- Kortekaas Krohn, I.; Badloe, F.M.S.; Herrmann, N.; Maintz, L.; De Vriese, S.; Ring, J.; CK-CARE Study Group; Bieber, T.; Gutermuth, J. Immunoglobulin E Autoantibodies in Atopic Dermatitis Associate with Type-2 Comorbidities and the Atopic March. Allergy 2023, 78, 3178–3192. [Google Scholar] [CrossRef]
- Lande, R.; Botti, E.; Jandus, C.; Dojcinovic, D.; Fanelli, G.; Conrad, C.; Chamilos, G.; Feldmeyer, L.; Marinari, B.; Chon, S.; et al. The Antimicrobial Peptide LL37 Is a T-Cell Autoantigen in Psoriasis. Nat. Commun. 2014, 5, 5621. [Google Scholar] [CrossRef]
- Chimenti, M.S.; Triggianese, P.; Nuccetelli, M.; Terracciano, C.; Crisanti, A.; Guarino, M.D.; Bernardini, S.; Perricone, R. Auto-Reactions, Autoimmunity and Psoriatic Arthritis. Autoimmun. Rev. 2015, 14, 1142–1146. [Google Scholar] [CrossRef]
- Valesini, G.; Gerardi, M.C.; Iannuccelli, C.; Pacucci, V.A.; Pendolino, M.; Shoenfeld, Y. Citrullination and Autoimmunity. Autoimmun. Rev. 2015, 14, 490–497. [Google Scholar] [CrossRef] [PubMed]
- Ziegelasch, M.; van Delft, M.A.M.; Wallin, P.; Skogh, T.; Magro-Checa, C.; Steup-Beekman, G.M.; Trouw, L.A.; Kastbom, A.; Sjöwall, C. Antibodies against Carbamylated Proteins and Cyclic Citrullinated Peptides in Systemic Lupus Erythematosus: Results from Two Well-Defined European Cohorts. Arthr. Res. Ther. 2016, 18, 289. [Google Scholar] [CrossRef]
- Lande, R.; Ganguly, D.; Facchinetti, V.; Frasca, L.; Conrad, C.; Gregorio, J.; Meller, S.; Chamilos, G.; Sebasigari, R.; Riccieri, V.; et al. Neutrophils Activate Plasmacytoid Dendritic Cells by Releasing Self-DNA–Peptide Complexes in Systemic Lupus Erythematosus. Sci. Transl. Med. 2011, 3, 73ra19. [Google Scholar] [CrossRef]
- Lande, R.; Palazzo, R.; Gestermann, N.; Jandus, C.; Falchi, M.; Spadaro, F.; Riccieri, V.; James, E.A.; Butera, A.; Boirivant, M.; et al. Native/Citrullinated LL37-Specific T-Cells Help Autoantibody Production in Systemic Lupus Erythematosus. Sci. Rep. 2020, 10, 5851. [Google Scholar] [CrossRef] [PubMed]
- Lande, R.; Pietraforte, I.; Mennella, A.; Palazzo, R.; Spinelli, F.R.; Giannakakis, K.; Spadaro, F.; Falchi, M.; Riccieri, V.; Stefanantoni, K.; et al. Complementary Effects of Carbamylated and Citrullinated LL37 in Autoimmunity and Inflammation in Systemic Lupus Erythematosus. Int. J. Mol. Sci. 2021, 22, 1650. [Google Scholar] [CrossRef]
- Willrich, M.A.V.; Murray, D.L.; Snyder, M.R. Tumor Necrosis Factor Inhibitors: Clinical Utility in Autoimmune Diseases. Depth Rev. New Ther. Targets Treat. Immunol. Disord. 2015, 165, 270–282. [Google Scholar] [CrossRef]
- Conrad, C.; Di Domizio, J.; Mylonas, A.; Belkhodja, C.; Demaria, O.; Navarini, A.A.; Lapointe, A.-K.; French, L.E.; Vernez, M.; Gilliet, M. TNF Blockade Induces a Dysregulated Type I Interferon Response without Autoimmunity in Paradoxical Psoriasis. Nat. Commun. 2018, 9, 25. [Google Scholar] [CrossRef] [PubMed]
- Strand, V.; Goncalves, J.; Isaacs, J.D. Immunogenicity of Biologic Agents in Rheumatology. Nat. Rev. Rheumatol. 2021, 17, 81–97. [Google Scholar] [CrossRef]
- Elliott, M.J.; Maini, R.N.; Feldmann, M.; Long-Fox, A.; Charles, P.; Bijl, J.A.; Woody, J.N. Repeated Therapy with Monoclonal Antibody to Tumour Necrosis Factor α (cA2) in Patients with Rheumatoid Arthritis. Orig. Publ. 1994, 344, 1125–1127. [Google Scholar] [CrossRef] [PubMed]
- Roda, G.; Jharap, B.; Neeraj, N.; Colombel, J.-F. Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management. Clin. Transl. Gastroenterol. 2016, 7, 135. [Google Scholar] [CrossRef]
- Cleynen, I.; Vermeire, S. Paradoxical Inflammation Induced by Anti-TNF Agents in Patients with IBD. Nat. Rev. Gastroenterol. Hepatol. 2012, 9, 496–503. [Google Scholar] [CrossRef]
- Vandercappellen, J.; Van Damme, J.; Struyf, S. The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer. Cytokine Growth Factor Rev. 2011, 22, 1–18. [Google Scholar] [CrossRef]
- van Bon, L.; Affandi, A.J.; Broen, J.; Christmann, R.B.; Marijnissen, R.J.; Stawski, L.; Farina, G.A.; Stifano, G.; Mathes, A.L.; Cossu, M.; et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N. Engl. J. Med. 2014, 370, 433–443. [Google Scholar] [CrossRef]
- Ah Kioon, M.D.; Tripodo, C.; Fernandez, D.; Kirou, K.A.; Spiera, R.F.; Crow, M.K.; Gordon, J.K.; Barrat, F.J. Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8. Sci. Transl. Med. 2018, 10, eaam8458. [Google Scholar] [CrossRef]
- Lande, R.; Mennella, A.; Palazzo, R.; Pietraforte, I.; Stefanantoni, K.; Iannace, N.; Butera, A.; Boirivant, M.; Pica, R.; Conrad, C.; et al. Anti-CXCL4 antibody reactivity is present in Systemic Sclerosis (SSc) and correlates with the SSc Type I Interferon signature. Int. J. Mol. Sci. 2020, 21, 5102. [Google Scholar] [CrossRef]
- Greinacher, A.; Warkentin, T.E. Platelet factor 4 triggers thrombo-inflammation by bridging innate and adaptive immunity. Int. J. Lab. Hematol. 2023, 45, 11–22. [Google Scholar] [CrossRef]
- Wang, X.; Mathieu, M.; Brezski, R.J. IgG Fc Engineering to Modulate Antibody Effector Functions. Protein Cell. 2018, 9, 63–73. [Google Scholar] [CrossRef] [PubMed]
- Chen, Q.; Vieth, M.; Timm, D.E.; Humblet, C.; Schneidman-Duhovny, D.; Chemmama, I.E.; Sali, A.; Zeng, W.; Lu, J.; Liu, L. Reconstruction of 3D Structures of MET Antibodies from Electron Microscopy 2D Class Averages. PLoS ONE 2017, 12, e0175758. [Google Scholar] [CrossRef] [PubMed]
- Strohl, W.R. Current Progress in Innovative Engineered Antibodies. Protein Cell 2018, 9, 86–120. [Google Scholar] [CrossRef] [PubMed]
- Losen, M.; Labrijn, A.F.; van Kranen-Mastenbroek, V.H.; Janmaat, M.L.; Haanstra, K.G.; Beurskens, F.J.; Vink, T.; Jonker, M.; ‘t Hart, B.A.; Mané-Damas, M.; et al. Hinge-Deleted IgG4 Blocker Therapy for Acetylcholine Receptor Myasthenia Gravis in Rhesus Monkeys. Sci. Rep. 2017, 7, 992. [Google Scholar] [CrossRef] [PubMed]
- Grönwall, C.; Vas, J.; Silverman, G. Protective Roles of Natural IgM Antibodies. Front. Immunol. 2012, 3, 66. [Google Scholar] [CrossRef] [PubMed]
- Ehrenstein, M.R.; Notley, C.A. The Importance of Natural IgM: Scavenger, Protector and Regulator. Nat. Rev. Immunol. 2010, 10, 778–786. [Google Scholar] [CrossRef] [PubMed]
- Baumgarth, N. B-1 Cell Heterogeneity and the Regulation of Natural and Antigen-Induced IgM Production. Front. Immunol. 2016, 7, 324. [Google Scholar] [CrossRef]
- Martin, F.; Kearney, J.F. B1 Cells: Similarities and Differences with Other B Cell Subsets. Curr. Opin. Immunol. 2001, 13, 195–201. [Google Scholar] [CrossRef]
- Baumgarth, N. The Double Life of a B-1 Cell: Self-Reactivity Selects for Protective Effector Functions. Nat. Rev. Immunol. 2011, 11, 34–46. [Google Scholar] [CrossRef]
- Berland, R.; Wortis, H.H. Origins and Functions of B-1 Cells with Notes on the Role of CD5. Annu. Rev. Immunol. 2002, 20, 253–300. [Google Scholar] [CrossRef] [PubMed]
- Chou, M.-Y.; Fogelstrand, L.; Hartvigsen, K.; Hansen, L.F.; Woelkers, D.; Shaw, P.X.; Choi, J.; Perkmann, T.; Bäckhed, F.; Miller, Y.I.; et al. Oxidation-Specific Epitopes Are Dominant Targets of Innate Natural Antibodies in Mice and Humans. J. Clin. Investig. 2009, 119, 1335–1349. [Google Scholar] [CrossRef] [PubMed]
- Tsiantoulas, D.; Gruber, S.; Binder, C. B-1 Cell Immunoglobulin Directed Against Oxidation-Specific Epitopes. Front. Immunol. 2013, 3, 415. [Google Scholar] [CrossRef] [PubMed]
- Binder, C.J.; Papac-Milicevic, N.; Witztum, J.L. Innate Sensing of Oxidation-Specific Epitopes in Health and Disease. Nat. Rev. Immunol. 2016, 16, 485–497. [Google Scholar] [CrossRef]
- Chen, Y.; Park, Y.-B.; Patel, E.; Silverman, G.J. IgM Antibodies to Apoptosis-Associated Determinants Recruit C1q and Enhance Dendritic Cell Phagocytosis of Apoptotic Cells1. J. Immunol. 2009, 182, 6031–6043. [Google Scholar] [CrossRef]
- Hakkim, A.; Fürnrohr, B.G.; Amann, K.; Laube, B.; Abed, U.A.; Brinkmann, V.; Herrmann, M.; Voll, R.E.; Zychlinsky, A. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc. Natl. Acad. Sci. USA 2010, 107, 9813–9818. [Google Scholar] [CrossRef]
- Brown, M.; O’Reilly, S. The Immunopathogenesis of Fibrosis in Systemic Sclerosis. Clin. Exp. Immunol. 2019, 195, 310–321. [Google Scholar] [CrossRef]
- Walker, U.A.; Tyndall, A.; Czirják, L.; Denton, C.; Farge-Bancel, D.; Kowal-Bielecka, O.; Müller-Ladner, U.; Bocelli-Tyndall, C.; Matucci-Cerinic, M. Clinical Risk Assessment of Organ Manifestations in Systemic Sclerosis: A Report from the EULAR Scleroderma Trials And Research Group Database. Ann. Rheum. Dis. 2007, 66, 754. [Google Scholar] [CrossRef]
- Simoni, Y.; Diana, J.; Ghazarian, L.; Beaudoin, L.; Lehuen, A. Therapeutic Manipulation of Natural Killer (NK) T Cells in Autoimmunity: Are We Close to Reality? Clin. Exp. Immunol. 2013, 171, 8–19. [Google Scholar] [CrossRef] [PubMed]
- Bosma, A.; Abdel-Gadir, A.; Isenberg, D.A.; Jury, E.C.; Mauri, C. Lipid-Antigen Presentation by CD1d+ B Cells Is Essential for the Maintenance of Invariant Natural Killer T Cells. Immunity 2012, 36, 477–490. [Google Scholar] [CrossRef] [PubMed]
- Irani, V.; Guy, A.J.; Andrew, D.; Beeson, J.G.; Ramsland, P.A.; Richards, J.S. Molecular Properties of Human IgG Subclasses and Their Implications for Designing Therapeutic Monoclonal Antibodies against Infectious Diseases. Ther. Antibod. Discov. Des. Deploy. 2015, 67, 171–182. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Frasca, L.; Mennella, A.; Palazzo, R. New, Old, and Shared Antibody Specificities in Autoimmune Diseases. Antibodies 2024, 13, 23. https://doi.org/10.3390/antib13010023
Frasca L, Mennella A, Palazzo R. New, Old, and Shared Antibody Specificities in Autoimmune Diseases. Antibodies. 2024; 13(1):23. https://doi.org/10.3390/antib13010023
Chicago/Turabian StyleFrasca, Loredana, Anna Mennella, and Raffaella Palazzo. 2024. "New, Old, and Shared Antibody Specificities in Autoimmune Diseases" Antibodies 13, no. 1: 23. https://doi.org/10.3390/antib13010023